Ciprofloxacin intratympanic - Otonomy

Drug Profile

Ciprofloxacin intratympanic - Otonomy

Alternative Names: AuriPro™; Ciprofloxacin otic suspension - Otonomy; OTIPRIO; OTO-201

Latest Information Update: 10 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otonomy
  • Class Antibacterials; Cyclopropanes; Fluoroquinolones; Piperazines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Otitis externa; Otitis media

Highest Development Phases

  • Marketed Otitis externa; Otitis media

Most Recent Events

  • 06 Aug 2018 Ciprofloxacin intratympanic market licensed for Otitis externa to Mission Pharmacal in USA
  • 08 Mar 2018 Otonomy has co-owned issued and pending patents for composition and therapeutic use of intratympanic ciprofloxacin in USA; issued patents or allowed applications in Australia, Canada, Europe, India, Israel, Japan, Korea, Mexico, Philippines, Russia, Singapore, South Africa and Taiwan; and pending applications in Argentina, Brazil, China, Jordan, Pakistan, Thailand, Uruguay and Venezuela
  • 08 Mar 2018 Otonomy has solely owned issued and pending patents for certain therapeutic uses of intratympanic ciprofloxacin in USA; pending applications in Australia, Brazil, Canada, China, Eurasia, Europe, Japan, Korea, and Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top